Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Major owner of GTx just picked up 9,686 shares
http://www.conferencecalltranscripts.org/4/summary2/?id=1818828
time to reload too
good luck all
good sign
insiders are getting laoding
ih.advfn.com/p.php?pid=nmona&article=67558031
ih.advfn.com/p.php?pid=nmona&article=67558020
july 2015 is our timeeeeeeeeeeeeeeeeee
(1)Study of the Effect of GTx-758 on Serum PSA and Testosterone in Men With Prostate Cancer
Condition: Prostate Cancer
Phase: Phase 2
Study Start: July 2012
Primary Completion: July 2015
Study Completion: November 2015
(2)Phase II Study of GTx024 in Women With Metastatic Breast Cancer
Condition: Metastatic Breast Cancer
Phase: Phase 2
Study Start: April 2013
Primary Completion: July 2015
Study Completion: September 2015
yea i think Q2 & Q3 will be interested for ( both 2 trials of Enobosarm and GTx-758 ).
Official Title: Phase II, Open Label Study of the Effect
of GTx-758 as Secondary Hormonal Therapy on Serum PSA and Serum Free Testosterone Levels in Men With Metastatic Castration Resistant Prostate Cancer Maintained on Androgen Deprivation Therapy
Estimated Enrollment: 76
Study Start Date: July 2012
Estimated Study Completion Date: November 2015
Estimated Primary Completion Date: July 2015 (Final data collection date for primary outcome measure)
as per company announcement its time to enroll an AR+ triple negative breast cancer (TNBC).
said Marc S. Hanover, CEO of GTx. “Additionally, our team continues to make good progress towards initiating our two planned Phase 2 clinical studies of enobosarm to treat advanced breast cancer, with the study in AR+ triple negative breast cancer expected to commence enrollment next month and our study of ER+/AR+ advanced breast cancer expected to start enrolling patients soon thereafter.”
Next month, the Company plans to commence enrollment in an open-label, proof-of-concept Phase 2 clinical trial of enobosarm in patients with advanced AR+ TNBC. The study will enroll up to 55 patients with the primary efficacy objective defined as clinical benefit at 16 weeks.
http://ih.advfn.com/p.php?pid=nmona&article=66767783
The Company plans to commence, in the first half of 2015, two additional open-label Phase 2 clinical trials of enobosarm; one in patients with ER positive and AR positive metastatic breast cancer and another in patients with advanced AR positive triple negative breast cancer.
http://ih.advfn.com/p.php?pid=nmona&article=64349183
yes , now almost the time to hear the result of GTx-758 as per their time frame :) hopefully we will hear GTx-758 in the next conference June 19
Once top-line results are available, which the Company expects early in the second quarter of 2015, the Company will evaluate potential next steps in the clinical development of GTx-758, including potentially seeking a partnering or collaboration agreement in order to fund additional clinical development.
ih.advfn.com/p.php?pid=nmona&article=64349183
i was asking when they will enroll the open label, P2 of enobosarm ( Androgen Receptor positive + Triple Negative Breast Cancer )
I just want to share what kind respond from Mr. Henry Doggrell ( Vice President, Chief Legal Officer ) in GTx.inc
From: Henry Doggrell <hdoggrell@gtxinc.com>
Date : 9 July 2015? : 6:22:67
To: "Fayez_q8@yahoo.com" <Fayez_q8@yahoo.com>
Subject : Your email question regarding AR+ and TNBC
Mr. Almutairi: thank you for your inquiry. We should have our first site for the clinical study operational in the next day or two and the others will come on line thereafter. As soon as we have enrolled our first patient into the study, we will issue a press release to that effect. When patients are identified by the PI for a clinical site, it will take 2 or 3 weeks to confirm their enrollment following the patient’s initial visit. Under the study protocol, the site has to confirm that the patient has met the enrollment criteria for the study. We are still anticipating that we will have enrolled our first patient later this month but that will depend on whether the initial subjects satisfy the enrollment criteria.
Thanks for your inquiry and your interest in GTx. Henry
Henry P. Doggrell
VP, Chief Legal Officer
GTx, Inc.
175 Toyota Plaza, 7th Floor
Memphis, Tennessee 38103
901-507-6916
20 on the ask
i'm happy coz i'm still here with my position and i'll continue increase my acount in CXAC
there are many parts i liked from the (LETTER TO SHAREHOLDERS)
As
Our results are in on the Internet Marketing Program we sold over 240 Re Juv by Caci Anti Aging Systems
Based upon the results we believe we will achieve the
500 unit figure that we projected for the month of September,
As per our public release we will combine the Internet program with television media in October in an effort to reach 1000 pieces for the month of
October.
If we can double our sales in less than 60 days we are off to the races!
----------
they sold 240, they'll achieve upto 500 units and they're in an effort to reach 1000 pieces next month.
if they reach thier target 1000 which is double what they projected .
((CXAC will be off to the race)).
Investment Highlights
CXAC’s three-year revenue goal is $9.3 million. Management expects to achieve this goal through placement of its products in major retail venues throughout North America. The first year post-funding, the Company expects to achieve revenues of $6.5 million.
The Company expects margins in excess of 20% from revenues in 2008.
CXAC announced in June 2008, that it had signed an 18 month marketing agreement that would entitle CXAC to direct access to nearly 4,000 top national food chains and major food club stores.
CXAC's product line includes a waterless car wash product that is an eco-friendly product that combines a bug removal, car cleaning solution and wax in one bottle, Fruit2 Go, a one of a kind packaged fruit product that is 100% Natural with no additives or preservatives, Re-Juv – Anti Wrinkle Cream which is a fast-acting anti-wrinkle cream as well as a super moisturizer and lastly, Dr. Beer Gourmet Pasta which is an organic, gourmet pasta.
According to the International Carwash Association (ICA), people spend more than $22 Billion for professional cleaning in 2008, whereas the Supermarket and grocery Industry (excluding Convenience Stores) hit $444 billion in 2005 growing to $720 billion by 2008 in the United States according to research by IBISWorld, a business analysis and reporting company.
CXAC announced in April 2008, that its newest division “Import Foods Division,” signed a leading European pasta manufacturer. The specialty pasta Company manufactures all natural and organic pasta. They are one of the largest specialty pasta companies in Europe, selling to all the major retailers in throughout Europe. Under the Import Foods Division program, CXAC will have a marketing budget of $200,000. This budget provides CXAC the flexibility to capture the major retailers in the U.S and Canada. CXAC also receives 10% on sales which could be as much as $2,000,000.
CXAC's management team is complimented by the Company’s national broker network of over fifty seasoned retail insiders.
Source :-http://allpennystocks.com/aps_us/company_spotlights/archives/cxac.asp
Regards,
Thanks ClayTrader for the nice CXAC video
hope we'll not talk long time to reach our 00's
Regards,
cong. buddies
good close .. and nice indicators in stockcharts.com for CXAC
GOOD LUCK ALL
this week was an active for CXAC
good job guys and thanks for keepin updating with CEO
hope we can see the same volume next week
Regards,
add me with MGLG please
Correction.. HWBI
hey lucy,, add me with HBWI plz ..
Regards,
My Pics is MDFI.. Regards
My Pich is MDFI.. Regards
ask is 0.001 now